152 related articles for article (PubMed ID: 36330692)
1. Effects of procalcitonin on antimicrobial treatment decisions in patients with coronavirus disease 2019 (COVID-19).
Conlon ASC; Chopra Z; Cahalan S; Cinti S; Rao K
Infect Control Hosp Epidemiol; 2023 Aug; 44(8):1314-1320. PubMed ID: 36330692
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic stewardship: Early discontinuation of antibiotics based on procalcitonin level in COVID-19 pneumonia.
Roy A; Powers HR; Craver EC; Nazareno MD; Yarrarapu SNS; Sanghavi DK
J Clin Pharm Ther; 2022 Feb; 47(2):243-247. PubMed ID: 34766357
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19.
Pink I; Raupach D; Fuge J; Vonberg RP; Hoeper MM; Welte T; Rademacher J
Infection; 2021 Oct; 49(5):935-943. PubMed ID: 34021897
[TBL] [Abstract][Full Text] [Related]
4. Procalcitonin to guide antibiotic decision making.
Branche A; Neeser O; Mueller B; Schuetz P
Curr Opin Infect Dis; 2019 Apr; 32(2):130-135. PubMed ID: 30648993
[TBL] [Abstract][Full Text] [Related]
5. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19.
Wolfisberg S; Gregoriano C; Schuetz P
Crit Rev Clin Lab Sci; 2022 Jan; 59(1):54-65. PubMed ID: 34517744
[TBL] [Abstract][Full Text] [Related]
6. Procalcitonin for antimicrobial stewardship among cancer patients admitted with COVID-19.
Dagher H; Chaftari AM; Mulanovich P; Jiang Y; Hachem R; Malek AE; Borjan J; Viola GM; Raad I
Elife; 2022 Dec; 11():. PubMed ID: 36541589
[TBL] [Abstract][Full Text] [Related]
7. The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19).
Fabre V; Karaba S; Amoah J; Robinson M; Jones G; Dzintars K; Katz M; Landrum BM; Qasba S; Gupta P; Klein E; Cosgrove SE
Infect Control Hosp Epidemiol; 2022 May; 43(5):570-575. PubMed ID: 33866995
[TBL] [Abstract][Full Text] [Related]
8. Procalcitonin-Guided Antibiotic Discontinuation Might Shorten the Duration of Antibiotic Treatment Without Increasing Pneumonia Recurrence.
Akagi T; Nagata N; Wakamatsu K; Harada T; Miyazaki H; Takeda S; Ushijima S; Aoyama T; Yoshida Y; Yatsugi H; Wada K; Ueda Y; Fujita M; Watanabe K
Am J Med Sci; 2019 Jul; 358(1):33-44. PubMed ID: 31084909
[TBL] [Abstract][Full Text] [Related]
9. Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study).
Henley J; Brookes-Howell L; Euden J; Pallmann P; Llewelyn M; Howard P; Powell N; Dark P; Szakmany T; Hellyer TP; Albur M; Hamilton R; Prestwich G; Ogden M; Maboshe W; Sandoe J; Thomas-Jones E; Carrol E; ;
BMJ Open; 2023 Dec; 13(12):e077117. PubMed ID: 38114276
[TBL] [Abstract][Full Text] [Related]
10. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department.
Tong-Minh K; van der Does Y; Engelen S; de Jong E; Ramakers C; Gommers D; van Gorp E; Endeman H
BMC Infect Dis; 2022 Feb; 22(1):165. PubMed ID: 35189826
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels.
So W; Simon MS; Choi JJ; Wang TZ; Williams SC; Chua J; Kubin CJ
Intern Emerg Med; 2022 Aug; 17(5):1405-1412. PubMed ID: 35277828
[TBL] [Abstract][Full Text] [Related]
12. Procalcitonin utilization in the real world: An observational study of antibiotic prescribing practices.
Choi JJ; Cornelius-Schecter A; Hayden JA; Jannat-Khah DP; O'Connell A; Baduashvili A; Lee J; McCarthy MW
J Eval Clin Pract; 2020 Aug; 26(4):1220-1223. PubMed ID: 31667954
[TBL] [Abstract][Full Text] [Related]
13. Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations.
Bremmer DN; DiSilvio BE; Hammer C; Beg M; Vishwanathan S; Speredelozzi D; Moffa MA; Hu K; Abdulmassih R; Makadia JT; Sandhu R; Naddour M; Chan-Tompkins NH; Trienski TL; Watson C; Obringer TJ; Kuzyck J; Walsh TL
J Gen Intern Med; 2018 May; 33(5):692-697. PubMed ID: 29404940
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of procalcitonin in cancer patients with coronavirus disease 2019.
Tiutan T; Wallins JS; Brown S; Gonen M; Korenstein D
Clin Chem Lab Med; 2023 Jan; 61(2):339-348. PubMed ID: 36367353
[TBL] [Abstract][Full Text] [Related]
15. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19.
Liu ZM; Li JP; Wang SP; Chen DY; Zeng W; Chen SC; Huang YH; Huang JL; Long W; Li M; Gao RF; Guo L; Wu XH
Int J Med Sci; 2020; 17(16):2468-2476. PubMed ID: 33029089
[No Abstract] [Full Text] [Related]
16. Evaluation of Procalcitonin's Utility to Predict Concomitant Bacterial Pneumonia in Critically Ill COVID-19 Patients.
Patel N; Adams C; Brunetti L; Bargoud C; Teichman AL; Choron RL
J Intensive Care Med; 2022 Nov; 37(11):1486-1492. PubMed ID: 35711161
[No Abstract] [Full Text] [Related]
17. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis.
Ni W; Bao J; Yang D; Xi W; Wang K; Xu Y; Zhang R; Gao Z
Infect Dis (Lond); 2019 Sep; 51(9):639-650. PubMed ID: 31355690
[No Abstract] [Full Text] [Related]
18. Procalcitonin-Guided Antibiotic Prescription in Patients With COVID-19: A Multicenter Observational Cohort Study.
Hessels LM; Speksnijder E; Paternotte N; van Huisstede A; Thijs W; Scheer M; van der Steen-Dieperink M; Knarren L; van Den Bergh JP; Winckers K; Henry R; Simsek S; Boersma WG;
Chest; 2023 Sep; 164(3):596-605. PubMed ID: 37116748
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Discordant Procalcitonin Use at an Academic Medical Center.
Seymann GB; Bevins N; Wu C; Fitzgerald R
Am J Clin Pathol; 2022 Jun; 157(6):890-898. PubMed ID: 34894127
[TBL] [Abstract][Full Text] [Related]
20. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study.
Atallah NJ; Warren HM; Roberts MB; Elshaboury RH; Bidell MR; Gandhi RG; Adamsick M; Ibrahim MK; Sood R; Bou Zein Eddine S; Cobler-Lichter MJ; Alexander NJ; Timmer KD; Atallah CJ; Viens AL; Panossian VS; Scherer AK; Proctor T; Smartt S; Letourneau AR; Paras ML; Johannes S; Wiemer J; Mansour MK
PLoS One; 2022; 17(1):e0262342. PubMed ID: 35025929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
